Description:

ApolycistronicmiRNAclustermiR-17-92playsaroleinthecontrolofcellproliferationandangiogenesis.ThisclusterconsistsofsevenmiRNAs:miR-17-5p,miR-17-3p,miR-18a,miR-19a,miR-19b,miR-20a,andmiR-92.LikeE2F1gene,theclusteristranscriptionallyactivatedbytheproto-oncogenec-Myc. BecausetwooftheexpressedmiRNAs,miR-17-5pandmiR-20a,repressthe translationofE2F1,thelevelofE2F1proteinismodulatedbythisfeedbackmechanism. Therefore,theaccumulationofexcessiveamountsofE2F1canbepreventedandthestatesofcellstowardsapoptosisorcelldivisioncanbecontrolled. Inaddition,c-MYC-mediatedinductionofthemiR-17-92clusterresultsindown-regulationoftheanti-angiogenicthrombospondin-1andrelatedproteins,suchasconnectivetissuegrowthfactor2;Therefore,itpromotesangiogenesis. FurThermore,arecentstudyindicatesthattheclusterissignificantlyup-regulatedattheclonalexpansionstageofADIpocytedifferentiation. ThemiR-17-92clusterhasbeenimplicatedastheoncogenesinnumeroustumortypes. EffectivemonitoringoftheexpressionoftheclusteredmiRNAscanhelpusbetterunderstandhowthealterationoftheclustercontributestodevelopmentofcancersandshedlightonthemolecularmechanismsofmiRNAfunction.

Principle:

IntheproprietarymiRNAplateassay,onemiRNAmoleculeisflankedbyacaptureoligoandabiotinateddetectionoligothroughtwobridgesoligos.OneofthebridgeoligosispartiallyhybridizedwiththemiRNAmoleculeandthecaptureoligoandanotherwiththemiRNAandthedetectionoligo.Thehybridisimmobilizedontoplatethroughhybridizationwithanimmobilizedoligoanddetectedbyastreptavidin-HRPconjugateandchemiluminecscentsubstrate.ThishybridstructureissensitivetothesequenceofthemiRNAmolecule.OnenucleotidedifferencewillpreventtheformationofthehybridandthereforemiRNAisoformcanbedifferentiated,whichnormallyishardtotacklewithNorthernblot.Inaddition,thesensitivityoftheassayishigherthanmiRNANorthernblotassay.

Data:

ExpressionofmiR-17-92clusterwasanalyzedwitho.5ugoftotalRNApreparedfromHeLaand293cellsthroughmiR-17-92clusterplatassay.Amongtheassays,HeLatotalRNAwasanalzyedthreetimes.

Signosis 是一家专业的生物分析供应商，致力于基于微孔板分析技术的生命科学研究产品的开发、生产和销售。Signosis 成立于2007年，坐落于世界研发中心--美国硅谷的中心地带。公司专注于细胞因子、转录因子、miRNA及疾病标志物等重要调控因子和标志物的研究，基于自有专利技术，开发完成400多种先进而独特的用于发现、筛选和分析的生命科学研究产品。Signosis 产品销售遍布北美、欧洲、亚洲及中东等主要国家和地区，客户涵盖美国国立卫生研究院、哈佛大学、耶鲁大学等著名研究机构以及众多制药公司